CCX832

CCX832 is an orally active molecule antagonist of chemerin at the chemokine receptor CMKLR1(ChemR2). ChemoCentryx, a pharmaceutical firm based in California, announced in April 2010 that they were successful in developing this medication in alliance with GlaxoSmithKline(GSK).